Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
SKYE Stock Forecast 2026-2027
$0.62
Current Price
$23.27M
Market Cap
Buy 6
Hold 2
Sell 0
Wall St Analyst Ratings
Distance to SKYE Price Targets
+3,125.3%
To High Target of $20.00
+867.6%
To Median Target of $6.00
+222.5%
To Low Target of $2.00
SKYE Price Momentum
-11.4%
1 Week Change
-15.1%
1 Month Change
-83.4%
1 Year Change
-17.3%
Year-to-Date Change
-87.6%
From 52W High of $4.99
+9.6%
From 52W Low of $0.57
📊 TOP ANALYST CALLS
Did SKYE Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Skye Bioscience is one of their latest high-conviction picks.
Latest SKYE Stock Price Targets & Analyst Predictions
Based on our analysis of 2 Wall Street analysts, SKYE has a bullish consensus with a median price target of $6.00 (ranging from $2.00 to $20.00). The overall analyst rating is Strong Buy (8.5/10). Currently trading at $0.62, the median forecast implies a 867.6% upside. This outlook is supported by 6 Buy, 2 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Ananda Ghosh at HC Wainwright & Co., projecting a 3,125.3% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
SKYE Analyst Ratings
6
Buy
2
Hold
0
Sell
SKYE Price Target Range
Low
$2.00
Average
$6.00
High
$20.00
Current: $0.62
Latest SKYE Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for SKYE.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Sep 30, 2025 | HC Wainwright & Co. | Ananda Ghosh | Buy | Initiates | $20.00 |
| Aug 15, 2025 | Evercore ISI Group | Outperform | Initiates | $N/A | |
| Jun 24, 2025 | JMP Securities | Market Outperform | Reiterates | $N/A | |
| Mar 21, 2025 | Craig-Hallum | Buy | Maintains | $N/A | |
| Mar 21, 2025 | Citizens Capital Markets | Market Outperform | Reiterates | $N/A | |
| Feb 28, 2025 | William Blair | Outperform | Initiates | $N/A | |
| Sep 30, 2024 | Scotiabank | Sector Outperform | Initiates | $N/A | |
| Sep 20, 2024 | Piper Sandler | Overweight | Reiterates | $N/A | |
| Sep 20, 2024 | Cantor Fitzgerald | Overweight | Reiterates | $N/A | |
| Sep 10, 2024 | JMP Securities | Market Outperform | Initiates | $N/A | |
| Sep 9, 2024 | Cantor Fitzgerald | Overweight | Reiterates | $N/A | |
| Sep 6, 2024 | Cantor Fitzgerald | Overweight | Reiterates | $N/A | |
| Aug 27, 2024 | Cantor Fitzgerald | Overweight | Reiterates | $N/A | |
| Jul 9, 2024 | Craig-Hallum | Buy | Initiates | $N/A | |
| Jul 1, 2024 | Cantor Fitzgerald | Overweight | Reiterates | $N/A | |
| Jun 18, 2024 | Cantor Fitzgerald | Overweight | Reiterates | $N/A | |
| Jun 17, 2024 | Cantor Fitzgerald | Overweight | Reiterates | $N/A | |
| May 23, 2024 | Cantor Fitzgerald | Overweight | Initiates | $N/A | |
| Apr 12, 2024 | Oppenheimer | Outperform | Initiates | $N/A | |
| Mar 14, 2024 | Piper Sandler | Overweight | Reiterates | $N/A |
Skye Bioscience Inc. (SKYE) Competitors
The following stocks are similar to Skye Bioscience based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
SKYE
Skye Bioscience
mkt cap
24.25M
Skye Bioscience Inc. (SKYE) Financial Data
Skye Bioscience Inc. has a market capitalization of $23.27M with a P/E ratio of 3.6x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -168.0%.
Valuation Metrics
Market Cap
$23.27M
Enterprise Value
$7.45M
P/E Ratio
3.6x
PEG Ratio
0.2x
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+78.5%
Current Ratio
1.8x
Debt/Equity
3.5x
ROE
-168.0%
ROA
-87.7%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Skye Bioscience Inc. (SKYE) Business Model
About Skye Bioscience Inc.
What They Do
Develops medicines targeting G-protein-coupled receptors.
Business Model
Skye Bioscience operates as a clinical stage biopharmaceutical company, focusing on developing innovative treatments that modulate the endocannabinoid system for metabolic and neurological disorders. The company generates revenue through partnerships and potential licensing agreements as its lead program, nimacimab, progresses through clinical trials, particularly targeting obesity treatment.
Additional Information
The company is based in San Diego, California, and its pipeline includes other promising candidates like SBI-100 Ophthalmic Emulsion for glaucoma. Skye aims to fill existing gaps in weight loss therapies by leveraging established biological pathways, enhancing its appeal to life science investors and positioning itself for regulatory milestones.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
2
CEO
Mr. Punit S. Dhillon B.A.
Country
United States
IPO Year
2021
Website
skyebioscience.comSkye Bioscience Inc. (SKYE) Latest News & Analysis
Latest News
Quick Summary
Skye Bioscience (NASDAQ: SKYE) announced the Cohort Review Committee approved opening enrollment for Cohort 2 of the CBeyond Part C Expansion Study, focusing on safety data for obesity treatments.
Why It Matters
The approval to open enrollment for Cohort 2 in Skye Bioscience's study signals progress in clinical trials, potentially enhancing investor confidence and impacting stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
UPDATE – Skye Bioscience Reports First Quarter 2026 Financial Results and Business Update
2 months ago
Quick Summary
Skye Bioscience (Nasdaq: SKYE) reported Q1 2026 financial results, focusing on developing G-protein-coupled receptor modulators for obesity and related conditions.
Why It Matters
Skye Bioscience's financial results and updates on their drug development for obesity could influence investor sentiment, affecting stock performance and future funding opportunities.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Skye Bioscience (Nasdaq: SKYE) reported Q1 2026 results, focusing on advancing its CBeyond program towards Phase 2b. Enrollment for the CBeyond Expansion Study has begun, with external advisors engaged for trial design.
Why It Matters
Skye Bioscience's progress in clinical development and enrollment for its Phase 2b study signals potential advancement in treatment options for obesity, impacting future valuations and market interest.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Kuehn Law is investigating potential fiduciary duty breaches by officers and directors of Skye Bioscience, Inc. (NASDAQ: SKYE), which could impact shareholder interests.
Why It Matters
Shareholder litigation could indicate potential wrongdoing at Skye Bioscience, impacting stock performance, investor confidence, and possible financial repercussions for the company.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Skye Bioscience, Inc. will present at the GLP-1-Based Therapeutics Summit in Boston on April 16, 2026, discussing their obesity treatment candidate, Nimacimab.
Why It Matters
Skye Bioscience's presentation on Nimacimab at a key summit could signal advancements in obesity treatment, potentially impacting stock performance and market perception in biotech.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Topline safety and pharmacokinetic data for the study is anticipated in Q4 2026, with oversight by an independent Data Monitoring Committee.
Why It Matters
Upcoming safety and pharmacokinetic data in Q4 2026 could impact stock valuations and investment decisions, indicating potential risks or opportunities in the company's pipeline.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About SKYE Stock
What is Skye Bioscience Inc.'s (SKYE) stock forecast for 2027?
Based on our analysis of 2 Wall Street analysts, Skye Bioscience Inc. (SKYE) has a median price target of $6.00. The highest price target is $20.00 and the lowest is $2.00.
Is SKYE stock a good investment in 2027?
According to current analyst ratings, SKYE has 6 Buy ratings, 2 Hold ratings, and 0 Sell ratings. The stock is currently trading at $0.62. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for SKYE stock?
Wall Street analysts predict SKYE stock could reach $6.00 in the next 12 months. This represents a 867.6% increase from the current price of $0.62. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Skye Bioscience Inc.'s business model?
Skye Bioscience operates as a clinical stage biopharmaceutical company, focusing on developing innovative treatments that modulate the endocannabinoid system for metabolic and neurological disorders. The company generates revenue through partnerships and potential licensing agreements as its lead program, nimacimab, progresses through clinical trials, particularly targeting obesity treatment.
What is the highest forecasted price for SKYE Skye Bioscience Inc.?
The highest price target for SKYE is $20.00 from Ananda Ghosh at HC Wainwright & Co., which represents a 3,125.3% increase from the current price of $0.62.
What is the lowest forecasted price for SKYE Skye Bioscience Inc.?
The lowest price target for SKYE is $2.00 from at , which represents a 222.5% increase from the current price of $0.62.
What is the overall SKYE consensus from analysts for Skye Bioscience Inc.?
The overall analyst consensus for SKYE is bullish. Out of 2 Wall Street analysts, 6 rate it as Buy, 2 as Hold, and 0 as Sell, with a median price target of $6.00.
How accurate are SKYE stock price projections?
Stock price projections, including those for Skye Bioscience Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 15, 2026 9:09 AM UTC